Company
Ogeda – former Euroscreen
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
New identity reflects Ogeda’s successful transition to GPCR drug discovery & development Ogeda develops drugs to validated GPCR targets in the areas of women’s health, inflammation and neurodegenerative diseases.
Loading relationship preview